Literature DB >> 12186455

Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.

Ana Laura Espinosa-de-los-Monteros1, Moisés Mercado, Ernesto Sosa, Oscar Lizama, Gerardo Guinto, Blas Lopez-Felix, Oscar Garcia, Irma Hernández, Alfonso Ovalle, Victoria Mendoza.   

Abstract

OBJECT: According to a recent consensus statement on the treatment of acromegaly, its biochemical cure is defined as the normalization of age- and sex-adjusted insulin-like growth factor (IGF)-I levels and the suppression of growth hormone (GH) by glucose to lower than 1 ng/ml. The present study was prompted by the clinical observation that many cases of acromegaly can be considered cured according to one criterion but not others at different moments in a patient's postoperative course.
METHODS: Fifty-three patients with acromegaly (30 women and 23 men) harboring nine microadenomas and 44 macroadenomas were evaluated after surgery by assessing age- and sex-adjusted IGF-I levels as well as glucose-suppressed GH levels. Fifty of these patients were studied more than once during follow up. Acromegaly was categorized as cured if the patient's IGF-I level was normal and their glucose-suppressed GH level was lower than 1 ng/ml; the disease was considered to be active if the patient's IGF-I level was high and the GH nadir was higher than 1 ng/ml following administration of glucose. Discordant categories of the disease were found in patients with high IGF-I levels and a GH nadir lower than 1 ng/ml after glucose administration and in those with normal IGF-I levels and a GH nadir higher than 1 ng/ml after glucose intake. At the first postoperative biochemical evaluation (1-3 months), 34% of patients harboring macroadenomas were classified as having been cured of acromegaly, 39% as having the active disease, and 27% as having the discordant form of the disease. When last evaluated (> or = 12 months postoperatively), the percentage of patients with the discordant form dropped to 14% and the proportion of cases cured and active was 44% and 41%, respectively. Of the nine patients with microadenomas, 44.4% were cured of acromegaly, 33.2% had the active disease, and 22% had the discordant variety on first evaluation. Twelve months or longer after transsphenoidal surgery, 55.5% of cases were cured, 11.1% were active, and 33% were discordant. In most cases, the discordant variety developed because of a persistently elevated level of IGF-I, followed by an incompletely suppressed GH level. Nineteen patients (38%) modified their biochemical category. In 15 of these patients this change in category was due to a change in IGF-I levels, becoming normal in 12 patients and rising to above normal range in three. A tumor remnant was demonstrated on magnetic resonance images in only four of these 19 patients.
CONCLUSIONS: The authors conclude that the discordance rate between the biochemical markers that define cure in acromegaly is higher than previously reported, and the biochemical status assigned to a patient early in the postoperative course is very likely to change later, particularly when initially discordant.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12186455     DOI: 10.3171/jns.2002.97.2.0287

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  6 in total

Review 1.  Biochemical investigations in diagnosis and follow up of acromegaly.

Authors:  Katharina Schilbach; Christian J Strasburger; Martin Bidlingmaier
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 2.  Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?

Authors:  Pamela U Freda
Journal:  Clin Endocrinol (Oxf)       Date:  2009-02-18       Impact factor: 3.478

Review 3.  Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.

Authors:  Mehdi Zeinalizadeh; Zohreh Habibi; Juan C Fernandez-Miranda; Paul A Gardner; Steven P Hodak; Sue M Challinor
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

Review 4.  Resistance to somatostatin analogs in acromegaly: an evolving concept?

Authors:  M Gola; S Bonadonna; G Mazziotti; G Amato; A Giustina
Journal:  J Endocrinol Invest       Date:  2006-01       Impact factor: 4.256

5.  Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly.

Authors:  Pamela U Freda; Jeffrey N Bruce; Carlos Reyes-Vidal; Simran Singh; Yessica DeLeon; Zhezhen Jin; Alexander G Khandji; Serge Cremers; Kalmon D Post
Journal:  Pituitary       Date:  2020-10-30       Impact factor: 4.107

6.  Medical therapy of acromegaly.

Authors:  U Plöckinger
Journal:  Int J Endocrinol       Date:  2012-04-10       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.